2024
11/15/2024
Boston Pharmaceuticals to Announce Positive Phase 2 Data on Efimosfermin Alfa (BOS-580) in F2/F3 MASH During Late-Breaking Oral Presentation at AASLD 2024, The Liver Meeting®
10/16/2024
Boston Pharmaceuticals to Present Phase 2 Biopsy Results for Long-Acting, Once-Monthly FGF21 Analogue Efimosfermin Alfa (BOS-580) in F2 and F3 MASH in Late-Breaking Oral Presentation at AASLD, The Liver Meeting® 2024
06/06/2024
Boston Pharmaceuticals Appoints Dr. Margaret Koziel as New Chief Medical Officer
06/05/2024
Boston Pharmaceuticals Presents Data at EASL Congress 2024 Showing Treatment With Long-acting FGF21 Analogue, BOS-580, Improved Lipid Profiles in Patients with Phenotypic MASH
05/23/2024
Boston Pharmaceuticals Announces Former NIH Director, Dr. Elias Zerhouni, As the New Chair of Its Board of Directors
01/05/2024
Boston Pharmaceuticals Presents Data at NASH-TAG 2024 Demonstrating Low Immunogenicity Over Time With Long-acting FGF21 Analogue, BOS-580, for MASH
2023
12/19/2023
Boston Pharmaceuticals Appoints Juan Carlos Lopez-Talavera, MD, PhD, as Acting Chief Medical Officer as MASH Asset BOS-580 Accelerates in Phase 2 Clinical Program
11/10/2023
Boston Pharmaceuticals Announces Positive Phase 2a Data Supporting Once-monthly Dosing With Investigational BOS-580 in NASH and Treatment Effects in Diabetic Subgroups at AASLD The Liver Meeting® 2023
11/7/2023
Boston Pharmaceuticals to Present New Phase 2a Data from Investigational BOS-580 NASH Program at AASLD The Liver Meeting® 2023
06/21/2023
Boston Pharmaceuticals Announces Positive Phase 2a Results from Monthly and Bi-weekly Dosing with Investigational BOS-580 NASH Program at EASL 2023
05/18/2023
Boston Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting New Phase 2 Clinical Data from BOS-580 NASH Program at EASL 2023
2022
05/10/2022
Boston Pharmaceuticals Appoints Dr. Sophie Kornowski as Chair of its Board of Directors and Acting Chief Executive
2021
10/4/2021
Boston Pharmaceuticals Doses First Patient in Phase 2a Clinical Trial of BOS-580 for NASH
4/26/2021
Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
3/18/2021
Boston Pharmaceuticals Enters into Unique Multi-Year Out-License and Option Agreement with GSK for the Advancement of Multiple Pre-Phase 2 Programs
2020
9/1/2020
Boston Pharmaceuticals Licenses NASH Development Candidate from Novartis
4/14/2020
Boston Pharmaceuticals Named One of the 2020 Best Workplaces in Health Care & Biopharma by Great Place to Work® and Fortune
